Namvar Kiaie Net Worth

Namvar Kiaie biography

Namvar Kiaie serves as Independent Director of the Company. Mr. Namvar Kiaie is a nominee for appointment as a director, and such appointment will be effective upon completion of this offering. Mr. Kiaie has been associated with Abbott Diabetes Care since December 2005 (Director of Engineering 2005-2007; R&D Director 2007-2010; and Senior Director of R&D 2010-present), where he is responsible for the commercial launch of diabetes management related products and accessories, including blood glucose monitoring devices and data management software. Mr. Kiaie graduated in 1985 with a Bachelor of Science degree in Electrical Engineering and in 1986 with a Master of Science degree in Electrical Engineering, both from the University of California Santa Barbara.

How old is Namvar Kiaie?

Namvar Kiaie is 54, he's been the Independent Director of ADiTx Therapeutics since 2020. There are 5 older and 5 younger executives at ADiTx Therapeutics. The oldest executive at ADiTx Therapeutics, Inc. is Dr. Joachim-Friedrich Kapp M.D., Ph.D., 79, who is the Sr. VP of Clinical Devel. - Autoimmunity.

What's Namvar Kiaie's mailing address?

Namvar's mailing address filed with the SEC is C/O ADITXT, INC., 737 N. FIFTH STREET, SUITE 200, RICHMOND, VA, 23219.

Insiders trading at ADiTx Therapeutics

Over the last 4 years, insiders at ADiTx Therapeutics have traded over $691,184 worth of ADiTx Therapeutics stock and bought 24,613 units worth $89,662 . The most active insiders traders include Paribas Securities Corp Bnp, Corinne Pankovcin und Jeffrey W. Runge. On average, ADiTx Therapeutics executives and independent directors trade stock every 93 days with the average trade being worth of $2,473. The most recent stock trade was executed by Paribas Securities Corp Bnp on 6 September 2023, trading 20,800 units of ADTX stock currently worth $691,184.

What does ADiTx Therapeutics do?

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

ADiTx Therapeutics executives and stock owners

ADiTx Therapeutics executives and other stock owners filed with the SEC include:

• Amro Albanna,
  Chairman of the Board, President, Chief Executive Officer
• Corinne D. Pankovcin CPA, CPA, M.B.A.,
  Pres
• Amro A. Albanna,
  Co-Founder, Chairman & CEO
• Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D.,
  Co-Founder, Chief Innovation Officer, Sec. & Director
• Shahrokh Shabahang,
  Chief Innovation Officer, Director
• Jeffrey Runge,
  Independent Director
• Namvar Kiaie,
  Independent Director
• Brian Brady,
  Independent Director
• Laura Anthony,
  Independent Director
• Rowena Albanna,
  Chief Operating Officer
• Corinne Pankovcin,
  Chief Financial Officer
• Dr. Joachim-Friedrich Kapp M.D., Ph.D.,
  Sr. VP of Clinical Devel. - Autoimmunity
• Dr. Dolly B. Tyan Ph.D.,
  Sr. VP of Clinical Devel. – Transplantation
• Jennifer Lee,
  Director of HR
• Matthew M. Shatzkes,
  Chief Legal Officer & Gen. Counsel
• Rowena Albanna,
  Chief Operating Officer
• Thomas J. Farley CPA,
  Chief Financial Officer
• Lauren Chung,
  Director
• Charles Athle Nelson,
  Director
• Thomas J Farley,
  Chief Financial Officer
• Paribas Securities Corp Bnp,